Bo Chu

Jan 19, 2025 | nature.com | Lei Zhang |Bo Chu

AbstractS-palmitoylation is a reversible and widespread post-translational modification, but its role in the regulation of ferroptosis has been poorly understood. Here, we elucidate that GPX4, an essential regulator of ferroptosis, is reversibly palmitoylated on cysteine 66. The acyltransferase ZDHHC20 palmitoylates GPX4 and increases its protein stability. ZDHHC20 depletion or inhibition of protein palmitoylation by 2-BP sensitizes cancer cells to ferroptosis.

Sep 10, 2024 | cell.com | Bo Chu |Cheeloo College

Keywordsgut microbial metabolismhost metabolismferroptosiscolorectal cancerGet full text accessLog in, subscribe or purchase for full access. References1. Wang, D. ... Regulatory pathways and drugs associated with ferroptosis in tumorsCell Death Dis. 2022; 13:5442. Uebanso, T. ... Functional roles of B-vitamins in the gut and gut microbiomeMol. Nutr. Food Res. 2020; 64, e20004263. Zhou, M. ... Vitamin B2-based ferroptosis promoter for sono-enhanced nanocatalytic therapy of triple-negative breast cancerAdv.

Nov 1, 2023 | nature.com | Yi Lu |Bo Chu

AbstractRecent findings have shown that fatty acid metabolism is profoundly involved in ferroptosis. However, the role of cholesterol in this process remains incompletely understood. In this work, we show that modulating cholesterol levels changes vulnerability of cells to ferroptosis. Cholesterol alters metabolic flux of the mevalonate pathway by promoting Squalene Epoxidase (SQLE) degradation, a rate limiting step in cholesterol biosynthesis, thereby increasing both CoQ10 and squalene levels.

Jun 8, 2023 | nature.com | Bo Chu |Jian Jin |Jingjie Yi

AbstractAlthough numerous studies indicate that inhibition of USP7 suppresses tumor growth by activating p53, the precise mechanism by which USP7 contributes to tumor growth through the p53-independent manner is not well understood. p53 is frequently mutated in most triple-negative breast cancers (TNBC), characterized as the very aggressive form of breast cancers with limited treatment options and poor patient outcomes.